AbCellera Biologics Inc. Company Profile
NASDAQ: ABCLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 12.10 +0.67%
AbCellera Biologics at a glance
AbCellera Biologics Inc. (NASDAQ: ABCL) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Vancouver, BC, Canada. AbCellera Biologics is led by Dr. Carl L.G. Hansen Ph.D. and employs about 562 people. The company's shares have traded publicly since 2020.
At a market capitalization of $3.90 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001703057, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does AbCellera Biologics do?
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Business description based on the company's public filings.
Company information
- Legal name
- AbCellera Biologics Inc.
- Ticker
- NASDAQ: ABCL
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Carl L.G. Hansen Ph.D.
- Employees
- 562
- Headquarters
- 150 W 4th Avenue, Vancouver, BC, Canada
- Phone
- 604 559 9005
- Website
- abcellera.com
- IPO year
- 2020
- Market cap
- $3.90B
- SEC CIK
- 0001703057
Companies similar to AbCellera Biologics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TNGXTango Therapeutics Inc. | 22.57 | +3.39% | $3.81B | vs ABCL |
| TLXTelix Pharmaceuticals Limited ADR | 11.01 | -0.99% | $3.74B | vs ABCL |
| LEGNLegend Biotech Corporation ADR | 18.71 | -2.14% | $3.64B | vs ABCL |
| OGNOrganon & Co. | 13.75 | -0.29% | $3.61B | vs ABCL |
| INDVIndivior Pharmaceuticals Inc. | 35.45 | -1.88% | $4.18B | vs ABCL |
| EWTXEdgewise Therapeutics Inc. | 39.23 | -0.86% | $4.26B | vs ABCL |
| VKTXViking Therapeutics Inc. | 27.73 | -2.84% | $3.53B | vs ABCL |
| XENEXenon Pharmaceuticals Inc. | 36.16 | -0.69% | $3.50B | vs ABCL |